Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This study aims to investigate the treatment of previously untreated stage I-II Extranodal
NK/T Cell Lymphoma with sintilimab, peg-aspargase and anlotinib, combined with radiotherapy.
The primary endpoint is response rate (complete response rate and overall response rate), and
the second endpoints are survival time (OS and PFS) and toxicities.